ENTITY
stringlengths 8
8
| DEFINITION
stringlengths 3
8.47k
⌀ | ALIASES
stringlengths 2
13.6k
⌀ | NAME
stringlengths 2
1.98k
|
|---|---|---|---|
C0251693 | null | immepip|4-IMP | 4-(1H-imidazol-4-ylmethyl)piperidine |
C0062739 | A class of histamine receptors discriminated by their pharmacology and mode of action. Histamine H3 receptors were first recognized as inhibitory autoreceptors on histamine-containing nerve terminals and have since been shown to regulate the release of several neurotransmitters in the central and peripheral nervous systems. (From Biochem Soc Trans 1992 Feb;20(1):122-5) | H3 Receptor, Histamine|Histamine H3 Receptors|Receptor, Histamine H3|H3 Receptors|H3 receptor|H3 Receptors, Histamine|Histamine H3 Receptor|Receptors, H3 | Receptors, Histamine H3 |
C0245109 | A synthetic form of native human IL-1Ra that has an additional methionine residue at its amino terminus. | Anakinra (substance)|rIL1RN|Kinaret|ANAKINRA|Anakinra|rIL-1ra|Product containing anakinra (medicinal product)|anakinra|IL-1RA|Interleukin-1 receptor antagonist anakinra|Anakinra-containing product | anakinra |
C0019214 | An abnormal enlargement of both the liver and spleen. | HEPATOSPLENOMEGALY|Hepatosplenomegaly (disorder)|hepatosplenomegaly|Enlarged liver and spleen|Hepatosplenomegaly | Hepatosplenomegaly |
C0585274 | null | Periodic syndrome (disorder)|periodic syndrome | Periodic syndrome |
C0600251 | An interleukin-1 subtype that occurs as a membrane-bound pro-protein form that is cleaved by proteases to form a secreted mature form. Unlike INTERLEUKIN-1BETA both membrane-bound and secreted forms of interleukin-1alpha are biologically active. | IL-1A|Hematopoietin-1|Hematopoietin 1|IL-1 alpha|Interleukin-1alpha|Interleukin-1 alpha (substance)|interleukin-1-alpha|Interleukin-1 alpha|Interleukin-1.Alpha.|Interleukin 1 alpha|Interleukin 1alpha | interleukin-1 alpha |
C1290884 | An infectious or non infectious disorder characterized by signs and symptoms derived from focal or extensive tissue infiltration by acute (e.g., polymorphonuclear) or chronic (e.g., lymphocytic-plasmacytic) inflammatory cells. Representative examples of infectious disorders include viral infections, bacterial infections, and parasitic infections. Representative examples of non-infectious inflammatory disorders include inflammatory bowel disease and inflammatory polyps. | disease inflammatory|Inflammatory disease|Inflammatory disorder (disorder)|Inflammatory Disease|disorders inflammatory|inflammatory disease|inflammatory disorder|diseases inflammatory|Inflammatory Disorder | Inflammatory disorder |
C0150097 | Studies comparing two or more treatments or interventions in which the subjects or patients, upon completion of the course of one treatment, are switched to another. In the case of two treatments, A and B, half the subjects are randomly allocated to receive these in the order A, B and half to receive them in the order B, A. A criticism of this design is that effects of the first treatment may carry over into the period when the second is given. (Last, A Dictionary of Epidemiology, 2d ed) | Studies, Crossover|Crossover Study|Trial, Cross-Over|Cross-Over Study|Study, Cross-Over|Crossover trials|Trial, Crossover|CROSS-OVER|Study, Crossover|Trials, Cross-Over|Studies, Cross-Over|Cross Over Studies|CROSSOVER TRIAL|Trials, Crossover|crossover trial|CROSSOVER|cross over trial|Crossover Studies|Crossover Trials|cross over study|crossover study|Cross Over Trials|Cross-Over Trials | Cross-Over Studies |
C0032042 | Any dummy medication or treatment. Although placebos originally were medicinal preparations having no specific pharmacological activity against a targeted condition, the concept has been extended to include treatments or procedures, especially those administered to control groups in clinical trials in order to provide baseline measurements for the experimental protocol. | fake drug|Placebo|PLCB|Placebo (Medicine)|placebos|Sham Treatment|sham treatment|placebo therapy|Placebos|placebo|Placebos (Medicine)|sham therapy | Placebos |
C0003129 | null | anoxaemia|anoxemia|Anoxaemia|Anoxemia | Anoxemia |
C1281065 | null | Entire diencephalon|Entire diencephalon (body structure) | Entire diencephalon |
C0003132 | null | anoxic brain injuries|Anoxic encephalopathy syndrome|Anoxic brain damage|Anoxic Encephalopathies|Encephalopathy, Anoxic|Anoxic Encephalopathy|Brain Damage, Anoxic|Anoxic encephalopathy, NOS|Anoxic encephalopathy (disorder)|brain anoxic damage|Damage, Anoxic Brain|Encephalopathies, Anoxic|Anoxic Brain Damage|anoxic brain injury|encephalopathy anoxic|anoxic brain damage|Anoxic encephalopathy|Anoxic brain damage, NOS|anoxic encephalopathy|Anoxic brain damage syndrome|Anoxic brain injury | Anoxic Encephalopathy |
C0039484 | Either of a pair of compound bones forming the lateral (left and right) surfaces and base of the skull which contains the organs of hearing. It is a large bone formed by the fusion of parts: the squamous (the flattened anterior-superior part), the tympanic (the curved anterior-inferior part), the mastoid (the irregular posterior portion), and the petrous (the part at the base of the skull). | TEMPORAL BONE|Temporal bone|Bone, Temporal|temporal bone|Temporal Bones|Temporal bone structure|Temporal bone, NOS|bones temporal|Temporal Bone|Os temporale|Temporal bone structure (body structure)|bone temporal|temporal bones | Temporal bone structure |
C0452138 | A bilateral form of sensorineural hearing impairment. [HPO:probinson] | Bilateral sensorineural hearing impairment|Sensorineural hearing loss, bilateral (disorder)|Deafness, sensorineural, bilateral|Hearing loss, sensorineural, bilateral|Sensorineural hearing loss, bilateral|Bilateral nerve deafness|Bilateral sensorineural deafness|Bilateral sensorineural hearing loss | Sensorineural hearing loss, bilateral |
C0013575 | A group of hereditary disorders involving tissues and structures derived from the embryonic ectoderm. They are characterized by the presence of abnormalities at birth and involvement of both the epidermis and skin appendages. They are generally nonprogressive and diffuse. Various forms exist, including anhidrotic and hidrotic dysplasias, FOCAL DERMAL HYPOPLASIA, and aplasia cutis congenita. | Ectodermal Dysplasia|ECTODERMAL DYSPLASIAS|ectodermal dysplasias|Ectodermal dysplasia|Ectodermal dysplasia syndrome|ectodermal dysplasia|congenital ectodermal dysplasia|Defects, Congenital Ectodermal|Congenital ectodermal dysplasia|Congenital Ectodermal Defects|dysplasia ectodermal|Ectodermal Defects, Congenital|Ectodermal Defect, Congenital|Ectodermal dysplasia, NOS|Ectodermal Dysplasia Syndromes|Ectodermal dysplasia (disorder)|Ectodermal Dysplasias|Dysplasias, Ectodermal|Congenital Ectodermal Defect|Congenital ectodermal defect (disorder)|Congenital ectodermal defect|Dysplasia, Ectodermal|Defect, Congenital Ectodermal | Ectodermal Dysplasia |
C0262496 | A molecular or cytogenic abnormality which occurs in either human disease states or disease models. | Cytogenetic or Molecular Genetic Abnormality|GENETIC ABNORMALITY|abnormalities genetic|Genetic Abnormality|Molecular Abnormality|genetic abnormality|Chromosomal, Gene, or Protein Abnormality|abnormality genetic | Molecular Abnormality |
C0476273 | A pathological increase in the effort and frequency of breathing movements. | Breathing difficulties|Respiratory distress|distressed breathing|RESPIRATORY DISTRESS|Respiratory distress (finding)|respiratory distress|Respiratory difficulties|Distressed respiration|Distressed breathing|Respiratory Distress|distressed respiratory|Distress, Respiratory|Difficulty breathing|DISTRESS RESPIRATORY | Respiratory distress |
C0008925 | Congenital fissure of the soft and/or hard palate, due to faulty fusion. | Cleft Palate|Cleft palate|Cleft palate, NOS|Uranoschisis|Cleft palate (disorder)|Palates, Cleft|Cleft Palates|cleft palates|Palate, Cleft|Cleft palate, unspecified|Cleft-palate|CP - Cleft palate|secondary cleft palate|Palatoschisis|CLEFT PALATE|PALATE CLEFT|cleft palate | Cleft Palate |
C0010090 | Broad plate of dense myelinated fibers that reciprocally interconnect regions of the cortex in all lobes with corresponding regions of the opposite hemisphere. The corpus callosum is located deep in the longitudinal fissure. | callosum corpus|Neocortical Commissures|corpus callosum|Corpus Callosums|Corpus callosum, NOS|Callosum, Corpus|Interhemispheric Commissure|Commissures, Interhemispheric|BRAIN, CORPUS CALLOSUM|Commissure, Neocortical|Intercerebral commissure|Corpus callosum structure (body structure)|Corpus callosum|Commissures, Neocortical|Neocortical Commissure|CC - Corpus callosum|Interhemispheric Commissures|Callosums, Corpus|Corpus callosum structure|CORPUS CALLOSUM|Commissure, Interhemispheric|Corpus Callosum | Corpus Callosum |
C0332907 | null | Agenesis|Absence, congenital|CONGENITAL ABSENCES|Congenital absence, NOS|Congenital absence|Congenital Absences|Congenital aplasia|congenital absence|Agenesis, NOS|Congenital aplasia, NOS|Congenital absence (morphologic abnormality)|agenesis|ABSENCE CONGENITAL | Congenital absence |
C0018821 | Surgery performed on the heart. | Operation on heart, NOS|Cardiac Surgery|Operation on heart|Operative procedure on heart|heart operations|Surgical Procedure, Heart|Heart Surgery|heart operation|Heart Surgical Procedure|Heart Surgical Procedures|Operative procedure on heart, NOS|Cardiac surgery procedure|heart surgeries|cardiac surgery procedure|Surgical Procedure, Cardiac|Surgical Procedures, Heart|Cardiac Surgical Procedures|Procedure, Heart Surgical|Surgical Procedures, Cardiac|Procedures, Cardiac Surgical|Operation on heart (procedure)|Cardiac Surgical Procedure|Procedures, Heart Surgical|cardiac operation|Cardiac surgery|cardiac operations|OPERATIVE PROCEDURES ON THE HEART|Cardiac surgery procedure, NOS|OR Heart Procedures|heart surgery|cardiac surgery procedures|Procedure, Cardiac Surgical | Cardiac Surgery procedures |
C0069436 | null | OSCP protein|ATP50 ATP synthase subunit|complex V|oligomycin sensitivity conferring protein|oligomycin sensitivity-conferring protein | oligomycin sensitivity-conferring protein |
C0086439 | Slow or diminished movement of body musculature. It may be associated with BASAL GANGLIA DISEASES; MENTAL DISORDERS; prolonged inactivity due to illness; and other conditions. | Hypoactivity, NOS|Decreased spontaneous movement|hypokinesia|Hypokinesis|lack of physical activity|Hypokinetic|Behavior showing reduced motor activity (finding)|decreased motor activity|Decreased muscle movement|Underactivity, NOS|Decreased motor activity, NOS|Hypoactive|hypokinesis|Hypokinesis, NOS|Hypokinesia, NOS|hypokinetic|Lack of physical activity|Behaviour showing reduced motor activity|Decreased activity|HYPOACTIVITY|Behavior showing reduced motor activity|Hypoactivity|Hypokinetic (qualifier value)|HYPOKINESIA|MOTOR ACTIVITY RETARDED|hypoactivity|Decreased spontaneous movements|Hypokinesia|Underactivity|ACTIVITY MOTOR RETARDED | Hypokinesia |
C0005791 | Any procedure in which blood is withdrawn from a donor, a portion is separated and retained, at the same time the remainder is returned to the donor. | Apheresis|blood component removal|phereses|Apheresis - action (qualifier value)|Removal, Blood Component|Therapeutic apheresis|Apheresis (procedure)|Hemapheresis|apheresis procedure|apherese|Therapeutic apheresis, NOS|aphereses|Apheresis procedure|Aphereses|hemapheresis|Apheresis - action|Blood Component Removals|Blood Component Removal|apheresis|Phereses|pheresis|Collection, Apheresis/Leukapheresis|therapeutic apheresis|Pheresis | Apheresis (procedure) |
C0221030 | any syndrome associated with increased viscosity of the blood; in syndrome of serum hyperviscosity there is spontaneous bleeding and neurologic and ocular disorders; syndromes of polycythemic hyperviscosity is marked by retarded blood flow, organ congestion, reduced capillary perfusion, and increased cardiac effort; syndromes of sclerocythemic hyperviscosity comprise those in which the deformability of erythrocytes is impaired, as in sickle cell anemia. | hyperviscosity syndrome|Hyperviscosity syndrome|Hyperviscosity syndrome (disorder)|HYPERVISCOSITY SYNDROME|Reimann's syndrome|hyperviscosity syndromes | Hyperviscosity syndrome |
C0032134 | Procedure whereby plasma is separated and extracted from anticoagulated whole blood and the red cells retransfused to the donor. Plasmapheresis is also employed for therapeutic use. | Plasmapheresis|plasmapheresis|Plasmaphereses|Plasmapheresis (procedure)|Therapeutic Plasmapheresis|Therapeutic plasmapheresis|Therapeutic Plasmaphereses|Therapeutic Plasma Exchange|Plasma Exchange|Plasmapheresis, Therapeutic|therapeutic plasmapheresis|plasmaphoresis | Plasmapheresis |
C1257880 | A collective term for a group of around nine geometric and positional isomers of LINOLEIC ACID in which the trans/cis double bonds are conjugated, where double bonds alternate with single bonds. | Linoleic Acids, Conjugated|CONJUGATED LINOLEIC ACID|conjugate linoleic acid|conjugated linoleic acids|acid conjugated linoleic|Acids, Conjugated Linoleic|Conjugated Linoleic Acids|Conjugated Linoleic Acid (CLA) | linoleic acids, conjugated |
C0004565 | null | B16 Melanoma|B16 Melanomas|Melanomas, B16|B16 Malignant Melanoma | Melanoma, B16 |
C0243038 | A carcinoma discovered by Dr. Margaret R. Lewis of the Wistar Institute in 1951. This tumor originated spontaneously as a carcinoma of the lung of a C57BL mouse. The tumor does not appear to be grossly hemorrhagic and the majority of the tumor tissue is a semifirm homogeneous mass. (From Cancer Chemother Rep 2 1972 Nov;(3)1:325) It is also called 3LL and LLC and is used as a transplantable malignancy. | Lung Carcinoma, Lewis|Lewis Lung Carcinoma | Carcinoma, Lewis Lung |
C1391732 | null | Cachexia due to malignant neoplastic disease (finding)|Cachexia due to malignant neoplastic disease | Malignant cachexia |
C0028688 | Facilities which provide nursing supervision and limited medical care to persons who do not require hospitalization. | Homes, Nursing|Nursing home, NOS|Nursing Homes|nursing homes|Home, Nursing|NH - Nursing home|Nursing home (environment)|NURSING HOME|Nursing home|Nursing Home|Long term care facility|Nursing homes|nursing home | Nursing Homes |
C0037817 | Communication through a system of conventional vocal symbols. | speech function|Talking|speech|Speech|Talk|Speech, NOS | Speech |
C0004093 | Clinical sign or symptom manifested as debility, or lack or loss of strength and energy. | Asthenic|asthenia|Asthenia NOS|Asthenia|ASTHENIA|Asthenia (finding) | Asthenia |
C1565743 | null | null | AM-411 |
C1565743 | null | null | AM-411 |
C1565743 | null | null | AM-411 |
C0085387 | Compounds or agents that combine with cyclooxygenase (PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES) and thereby prevent its substrate-enzyme combination with arachidonic acid and the formation of eicosanoids, prostaglandins, and thromboxanes. | Prostaglandin Endoperoxide Synthase Inhibitors|COX inhibitor|Antagonists, Prostaglandin Synthesis|Inhibitors, Prostaglandin-Endoperoxide Synthase|Prostaglandin Synthase Inhibitors|Clyclooxygenases Inhibitor|cyclo-oxygenase inhibitors|Prostaglandin-endoperoxide synthase inhibitor|cyclooxygenase inhibitors|Cyclooxygenase inhibitor|Cyclooxygenase Inhibitor|Inhibitors, Cyclo Oxygenase|prostaglandin endoperoxide synthase inhibitor|Substance with prostaglandin-endoperoxide synthase inhibitor mechanism of action (substance)|Cyclo-Oxygenase Inhibitors|COX Inhibitor|Inhibitors, Cyclo-Oxygenase|Cyclooxygenase Inhibitors|Prostaglandin Synthesis Antagonists|Inhibitors, Prostaglandin Synthase|cyclooxygenase inhibitor|inhibitors prostaglandin synthase|PTGS inhibitor|Inhibitors, Prostaglandin Endoperoxide Synthase|Inhibitors, Cyclooxygenase|Cyclo Oxygenase Inhibitors|Prostaglandin G/H Synthase Inhibitor | Cyclooxygenase Inhibitors |
C0599788 | null | care seeking | care seeking |
C0750979 | null | Primary Malignant Brain Neoplasms|Malignant Primary Brain Tumors|Brain Neoplasms, Primary Malignant|Primary Malignant Brain Tumors|Brain Neoplasms, Malignant, Primary|Primary malignant neoplasm of brain|Primary malignant neoplasm of brain (disorder)|Malignant Primary Brain Neoplasms | Primary malignant neoplasm of brain |
C0231303 | Extreme mental or physical pain or suffering. | distressing|distress|Distress (finding)|Distress, NOS|Distress | Distress |
C0376562 | A recombinant therapeutic agent which is chemically identical to or similar to the endogenous cytokine granulocyte colony-stimulating factor (G-CSF). Secreted by monocytes, macrophages and neutrophils and other cells after activation, G-CSF stimulates the proliferation and differentiation of hematopoietic progenitor cells committed to the neutrophil/ granulocyte lineage. (NCI04) | Recombinant Colony-Stimulating Factor 3|rhG-CSF|Recombinant Granulocyte Colony-Stimulating Factor | Recombinant Granulocyte Colony Stimulating Factor |
C0013018 | One that contributes something. | DONOR|Donors|donor|Donor|donors | Donor person |
C0729538 | A vessel graft comprised of the saphenous vein. | saphenous vein graft|Saphenous vein graft|grafts saphenous vein|Saphenous Vein Graft|Saphenous vein graft (substance)|SAPHENOUS VEIN GRAFT|SVG | Saphenous vein graft |
C0225819 | Border of heart between the posterior and lateral walls of the left ventricle. | Left margin of heart|Structure of left margin of heart (body structure)|Obtuse margin of heart|Left border of heart viewed radiologically|Structure of left margin of heart|Left border of heart (viewed radiologically) | Structure of left margin of heart |
C0018826 | Flaps of tissue that prevent regurgitation of BLOOD from the HEART VENTRICLES to the HEART ATRIA or from the PULMONARY ARTERIES or AORTA to the ventricles. | CARDIAC VALVE|cardiac valve|VALVE, CARDIAC|Heart Valve|Valves, Cardiac|Cardiac valve structure (body structure)|cardiac valves|valve of heart|Heart valve|Valves, Heart|heart valves|Heart Valves|Cardiac valve structure|Cardiac Valves|Cardiac Valve|Heart valves|Valve, Heart|Valve of heart|heart valve|CARDIAC VALVES: GENERAL TERMS|Cardiac valve, NOS|Heart valve structure|CARDIAC VALVES|Cardiac valve|Valve, Cardiac | Heart Valves |
C0016356 | Production of an image when x-rays strike a fluorescent screen. | Fluoroscopic imaging - action|Fluoroscopy (procedure)|FLUOROSCOPY|Fluoroscopic imaging - action (qualifier value)|Fluoroscopy technique|Fluoroscopy|Fluoroscopic imaging|Fluoroscopies|Fluoroscopy, NOS|fluoroscopy | Fluoroscopy |
C0700586 | null | Interatrial fistulization|Formation of interatrial fistula|Blalock-Hanlon operation|Creation of atrial septal defect|Creation of interatrial fistula|Blalock Hanlon operation (procedure)|Formation of interatrial septal defect|BH - Blalock Hanlon atrial septectomy|atrial septostomy|Blalock Hanlon operation|Atrial septostomy | Blalock Hanlon operation |
C0039409 | The fluid secreted by the lacrimal glands. This fluid moistens the CONJUNCTIVA and CORNEA. | tearing|tear from eye|tear|TEAR|teardrop|Tears (substance)|Portion of tear|tears|Tear|Tears | Tears body substance |
C0001973 | A primary, chronic disease with genetic, psychosocial, and environmental factors influencing its development and manifestations. The disease is often progressive and fatal. It is characterized by impaired control over drinking, preoccupation with the drug alcohol, use of alcohol despite adverse consequences, and distortions in thinking, most notably denial. Each of these symptoms may be continuous or periodic. (Morse & Flavin for the Joint Commission of the National Council on Alcoholism and Drug Dependence and the American Society of Addiction Medicine to Study the Definition and Criteria for the Diagnosis of Alcoholism: in JAMA 1992;268:1012-4) | chronic alcoholism|alcohol dependence|alcohol dependences|alcoholism|Intoxication, Chronic Alcoholic|Alcoholic dependence syndrome|ALCOHOL DEPENDENCE|ALCOHOLISM|Alcohol dependence (disorder)|Dependence, Alcohol|Alcoholic Intoxication, Chronic|Alcoholism, chronic|Alcoholism with alcohol dependence|Chronic alcohol abuse|Alcohol Dependence|alcohol dependency|Alcohol Addiction|alcoholism disorders|Chronic alcoholism|Addiction, alcohol|Dipsomania|chronic alcohol abuse|Alcohol dependence|Alcoholism (disorder)|alcoholisms|dependence alcoholism alcohol|dipsomania|alcoholism chronic disorders|Addiction, Alcohol|Alcoholism|Persistent alcohol abuse (disorder)|Alcohol problem drinking|Alcohol dependence syndrome|alcohol dependence syndrome|alcohol addiction|alcoholism/alcohol abuse|Persistent alcohol abuse|Alcoholism, NOS|Chronic Alcoholic Intoxication|abuse alcohol alcoholism|addiction alcohol|alcohol abuse alcoholism|alcoholism chronic|disorder alcoholism | Alcoholic Intoxication, Chronic |
C0008550 | Techniques used to separate mixtures of substances based on differences in the relative affinities of the substances for mobile and stationary phases. A mobile phase (fluid or gas) passes through a column containing a stationary phase of porous solid or liquid coated on a solid support. Usage is both analytical for small amounts and preparative for bulk amounts. | Chromatographies|CHROMATOGRAPHY|Chromatography/Separation Science|Chromatography / Separation Science|chromatography|Chromatography | Chromatography |
C0011142 | Unconscious process used by an individual or a group of individuals in order to cope with impulses, feelings or ideas which are not acceptable at their conscious level; various types include reaction formation, projection and self reversal. | Ego defense mechanisms|Mechanisms, Defense|Ego defence mechanisms|defense mechanisms|psychological defense mechanism|ego defense mechanisms|defense mechanisms psychological|Mental defense mechanisms (observable entity)|Mental defense mechanisms|Mental defence mechanisms|defense mechanism | Defense Mechanisms |
C0009516 | Complement component-4 (1744 aa, ~193 kDa) is part of the complement cascade, which mediates the innate immune response to infection. The full length protein is a precursor that is secreted as a trimeric molecule containing an alpha, beta and gamma chain. When the complement cascade is initiated, the protein is cleaved. This proteolysis releases both the alpha chain, C4 anaphylatoxin, which stimulates inflammation, and a dimer of the beta and gamma chains, which mediates the interaction between the antigen-antibody complex and other complement components. | complement 4|complement component 4|complement component c4|Component 4, Complement|Component, C4 Complement|Complement, C4|C4 Complement Component|Complement Component, C4|C4, Complement|C4|C4 - Complement component 4|Complement 4|Complement C4|Complement component C4|complement c4|Complement-fourth component-C4|Complement Component 4|Complement component C4, NOS|C4 Complement|Complement Component-4|Complement component C4 (substance) | Complement component C4 |
C0000720 | null | Abbott 48999|Abbott48999 | Abbott-48999 |
C1413721 | null | HAPLN1 gene|CRTL1|hyaluronan and proteoglycan link protein 1|Cartilage link protein|HYALURONAN AND PROTEOGLYCAN LINK PROTEIN 1|CARTILAGE LINK PROTEIN|HAPLN1 | HAPLN1 gene |
C1413721 | null | HAPLN1 gene|CRTL1|hyaluronan and proteoglycan link protein 1|Cartilage link protein|HYALURONAN AND PROTEOGLYCAN LINK PROTEIN 1|CARTILAGE LINK PROTEIN|HAPLN1 | HAPLN1 gene |
C1442179 | null | null | Amniotic Fluid cells |
C0037017 | null | Shrimp|shrimps|shrimp|Shrimp, NOS|Shrimps | Shrimp |
C0020517 | Altered reactivity to an antigen, which can result in pathologic reactions upon subsequent exposure to that particular antigen. | Allergies|Hypersensitivity reaction (disorder)|hypersensitivity|hypersensitivity symptom|hypersensitivities|allergies|Hypersensitive|Allergic Reaction|HYPERSENSITIVITY REACTION (NOS)|Sensitivity|ALLERGIC REACTION (NOS)|Allergic reaction, NOS|Sensitive|Allergic disorders|allergy|Allergic state, NOS|Hypersensitivity|Allergy|Allergic reaction caused by substance|hypersensitivity reactions|allergic reaction|ALLERGY|hypersensitivity reaction|allergy disorders|REACTION HYPERSENSITIVITY (NOS)|allergic reactions|Allergic state|ALLERGIC/HYPERSENSITIVITY|Allergic reaction to substance|hypersensitivity symptoms|HYSN|Allergy, NOS|Allergic reaction NOS|ALLERGIC REACTION|Hypersensitivity NOS|allergic disorders|REACTION ALLERGIC (NOS)|Hypersensitivity Reaction|allergic disorder|Allergic reaction|Hypersensitivity reaction|Hypersensitivity reaction, NOS|Allergic reaction caused by substance (disorder)|Hypersensitivities | Hypersensitivity |
C0020985 | Immunologic method used for detecting or quantifying immunoreactive substances. The substance is identified by first immobilizing it by blotting onto a membrane and then tagging it with labeled antibodies. | Immunoblot assay technique|immunoblot|IMMUNOBLOT|Immunoblot assay (procedure)|Immunoblot assay technique (qualifier value)|Immunoblotting (qualifier value)|immunoblotting|Immunoblot|Immunoblottings|assays immunoblot|Immunoblot assay|Immunoblot Assay|Immunoblotting|immunoblot assay|Immunoblot assay, NOS|Immunoblot Analysis | Immunoblotting |
C0004271 | An enduring, learned predisposition to behave in a consistent way toward a given class of objects, or a persistent mental and/or neural state of readiness to react to a certain class of objects, not as they are but as they are conceived to be. | attitude|Outlook|Attitude (observable entity)|Attitude|Attitudes|attitudes | Attitude |
C0019932 | Chemical substances having a specific regulatory effect on the activity of a certain organ or organs. The term was originally applied to substances secreted by various ENDOCRINE GLANDS and transported in the bloodstream to the target organs. It is sometimes extended to include those substances that are not produced by the endocrine glands but that have similar effects. | hormone|hormone drug|drug hormones|Endocrine Gland Secretion|Hormone (substance)|Hormone preparation|Hormone-containing product|Hormone product, NOS|drugs hormones|Hormone, NOS|Hormone agent, NOS|drugs hormone|Product containing hormone (product)|Hormone preparation, NOS|Hormone drug, NOS|HORMONE PREPARATIONS|Hormone|Endocrine substance preparation, NOS|hormones|Hormones|hormones preparation | Hormones |
C0242849 | A type of scanning probe microscopy in which a probe systematically rides across the surface of a sample being scanned in a raster pattern. The vertical position is recorded as a spring attached to the probe rises and falls in response to peaks and valleys on the surface. These deflections produce a topographic map of the sample. | Atomic Force Microscopy|AFM|Microscopy, Force|Force Microscopy, Scanning|Microscopies, Scanning Force|atomic force microscopy|Microscopies, Atomic Force|Atomic force microscopy|Microscopy, Scanning Force|Microscopy, Atomic Force|afm|Force Microscopies, Scanning|scanning force microscopy|Atomic Force Microscopies|Microscopies, Force|Scanning Force Microscopy|Force Microscopies|Scanning Force Microscopies|Force Microscopy|atomic force microscope (AFM) | Microscopy, Atomic Force |
C1527144 | Beneficial responses or outcomes in the prevention, treatment, or progression of a disease resulting from treatment intervention. Therapeutic effect includes prevention or reduction of adverse effects. (NCI) | Effects, Therapeutic|Therapeutic Effects|Therapeutic Effect | Therapeutic Effect |
C0017296 | The processes by which highly specific gene sequences in a host cell are targeted and regulated for the purpose of reversing and or curing a disease. | Gene Therapy|Intervention, Genetic|Therapy, Gene|therapy, gene|GENETIC|Gene Transfer Procedure|gene therapy|dna therapy|gene therapies|Molecular Biology, Gene Therapy|dna therapies|DNA Therapy|Gene therapy (procedure)|Gene therapy|Gene transfer | gene therapy |
C0009413 | The thin, yellow, serous fluid secreted by the mammary glands during pregnancy and immediately postpartum before lactation begins. It consists of immunologically active substances, white blood cells, water, protein, fat, and carbohydrates. | Colostrum (substance)|Colostrum|First milk|Colostrums|colostrums|Foremilk|colostrum | Colostrum |
C0024069 | The application of LUBRICANTS to diminish FRICTION between two surfaces. | Lubrications|lubrication|Lubrication | Lubrication |
C0024069 | The application of LUBRICANTS to diminish FRICTION between two surfaces. | Lubrications|lubrication|Lubrication | Lubrication |
C0394664 | Treatment of disease by inserting needles along specific pathways or meridians. The placement varies with the disease being treated. It is sometimes used in conjunction with heat, moxibustion, acupressure, or electric stimulation. | Acupuncture, NOS|therapy acupuncture|Acupuncture|Acupuncture Therapy|Acupuncture Treatment|Other Procedures @ Physiological Systems and Anatomical Regions @ Other Procedures @ Integumentary System and Breast @ Percutaneous @ Acupuncture @ No Qualifier|ACP - Acupuncture|acupuncture therapy|Therapy, Acupuncture|Acupuncture (procedure)|acupuncture|Treatment, Acupuncture|Acupuncture Treatments | Acupuncture procedure |
C1312983 | null | null | binary ethyleneimine |
C1519689 | The second step in two-stage carcinogenesis: the conversion of an initiated (premalignant) cell to malignancy. | tumor promotion | Tumor Promotion |
C1512409 | The processes which result in cancers in the liver. | Liver Carcinogenesis | Hepatocarcinogenesis |
C0085180 | A potent hepatotoxic and hepatocarcinogenic mycotoxin produced by the Aspergillus flavus group of fungi. It is also mutagenic, teratogenic, and causes immunosuppression in animals. It is found as a contaminant in peanuts, cottonseed meal, corn, and other grains. The mycotoxin requires epoxidation to aflatoxin B1 2,3-oxide for activation. Microsomal monooxygenases biotransform the toxin to the less toxic metabolites aflatoxin M1 and Q1. | AFB1|Cyclopenta(c)furo(3',2':4,5)furo(2,3-h)(1)benzopyran-1,11-dione, 2,3,6a,9a-tetrahydro-4-methoxy-, (6aR-cis)-|aflatoxin b1|Aflatoxin B1|b1 aflatoxin|AFLATOXIN B1|(6AR-cis)-2,3,6a,9a-tetrahydro-4-methoxycyclopenta(c)furo(3',2':4,5)furo(2,3-h)(1)benzopyran-1,11-dione | Aflatoxin B1 |
C0034804 | Cytoplasmic proteins that bind estrogens and migrate to the nucleus where they regulate DNA transcription. Evaluation of the state of estrogen receptors in breast cancer patients has become clinically important. | Estrogen Receptors|ER|ER Family|estrogen receptor (ER)|Nuclear Receptor Subfamily 3 Group A|oestrogen receptor|estrogen receptors|Oestrogen receptor site|Estrogen receptor site|E2R - estrogen receptor|Estradiol Receptor|Estrogen Receptor Family|Receptors, Estrogen|Estrogen Receptor Family Protein|Estrogen receptor|NR3A|estrogen receptor|Estrogen Receptor|Estrogen receptor (substance)|Estrogen--Receptors | Estrogen Receptors |
C0596196 | measures moles per liter of blood; increases with dehydration and decreases with overhydration; normal osmolarity is contributed to mostly by sodium, chloride, potassium, urea and glucose, as well as other ions and substances in the blood. | blood osmolarity|osmolarity blood | blood osmolarity |
C0596196 | measures moles per liter of blood; increases with dehydration and decreases with overhydration; normal osmolarity is contributed to mostly by sodium, chloride, potassium, urea and glucose, as well as other ions and substances in the blood. | blood osmolarity|osmolarity blood | blood osmolarity |
C1516463 | A natural or synthetic substance, such as a drug, vitamin, hormone, plant product or food supplement, that may reduce the risk of developing or recurrence of tumor formation. Chemopreventive agent may work at different stages and may inhibit the initiation, promotion, transformation, and/or progression of the malignant process. | null | Chemopreventive Agent |
C0851121 | null | digestive problems | digestive problem |
C0242350 | The inability in the male to have a PENILE ERECTION due to psychological or organ dysfunction. | Difficulty getting a full erection|Failure of erection|dysfunction erectile|Impotence, Male|dysfunctioning erectile|erectile dysfunction|Impotence, NOS|Male Sexual Impotence|Impotence|Male erectile disorder|erectile dysfunctions|Erectile Dysfunction|erection dysfunction|Impotent|ED|impotence|Erectile dysfunction|Impotence (disorder)|Male Impotence|sexual impotence|IMPOTENCE|Dysfunction, Erectile|Difficulty getting an erection|impotent|Sexual Impotence, Male|Male Erectile Disorder|Sexual impotence|Sexual impotence, NOS|male erectile disorder|dysfunction erection|PENILE ERECTION IMPAIRMENT|Impotence, Male Sexual | Erectile dysfunction |
C0041740 | Educational institutions providing facilities for teaching and research and authorized to grant academic degrees. | University (environment)|universities|UNIV|University|university | Universities |
C0521168 | Injuries sustained from incidents in the course of work-related activities. | Injuries, Occupational|injuries occupational|Occupational Injuries|Occupational injury, NOS|Occupational injury|Injury, Occupational|Occupational injury (disorder)|occupational injury|Occupational Injury | Occupational Injuries |
C0586557 | null | Accident while engaged in work-related activity (event)|Accident while engaged in work-related activity|Accident whilst engaged in work-related activity|accidents work|Accident at work, NOS|accidents works|Accident while engaged in work-related activity, NOS|accident at work|ACCIDENTS WHILE ENGAGED IN WORK-RELATED ACTIVITIES|Accident at work|Work accident | Accident while engaged in work-related activity |
C1140621 | The inferior part of the lower extremity between the KNEE and the ANKLE. | Structure of lower extremity from knee to ankle|Lower hindlimb|Leg|Lower leg structure|Lower leg|Crus|Crural region|leg|LEG|Legs|Structure of lower extremity from knee to ankle (body structure)|lower leg|Intermediate segment of free lower limb|legs|Leg, NOS | Leg |
C0021641 | A 51-amino acid pancreatic hormone that plays a major role in the regulation of glucose metabolism, directly by suppressing endogenous glucose production (GLYCOGENOLYSIS; GLUCONEOGENESIS) and indirectly by suppressing GLUCAGON secretion and LIPOLYSIS. Native insulin is a globular protein comprised of a zinc-coordinated hexamer. Each insulin monomer containing two chains, A (21 residues) and B (30 residues), linked by two disulfide bonds. Insulin is used as a drug to control insulin-dependent diabetes mellitus (DIABETES MELLITUS, TYPE 1). | Unmodified insulin preparation|regular insulin|Insulin|insulin|insulin regular|Product containing insulin (product)|insulin preparations|insulins|Regular Insulin|Regular insulin preparation|insulin products|Insulin, Soluble|insulin preparation|insulin product|INSULIN PREPARATIONS|Insulin (substance)|Insulin, Regular|Soluble Insulin|Insulin preparation, NOS|Insulin-containing product | Insulin |
C0024530 | A protozoan disease caused in humans by four species of the PLASMODIUM genus: PLASMODIUM FALCIPARUM; PLASMODIUM VIVAX; PLASMODIUM OVALE; and PLASMODIUM MALARIAE; and transmitted by the bite of an infected female mosquito of the genus ANOPHELES. Malaria is endemic in parts of Asia, Africa, Central and South America, Oceania, and certain Caribbean islands. It is characterized by extreme exhaustion associated with paroxysms of high FEVER; SWEATING; shaking CHILLS; and ANEMIA. Malaria in ANIMALS is caused by other species of plasmodia. | malarial fever|malaria|Plasmodiosis|Malarial fever|Infections, Plasmodium|fever malaria|Malaria|malarias|Paludism|Fever, Marsh|Infection, Plasmodium|Plasmodium Infection|paludism|Malaria, unspecified|Malarial fever (finding)|Malaria (disorder)|DISEASES DUE TO PLASMODIIDAE|Malaria, NOS|Disease caused by Plasmodiidae (disorder)|Disease due to Plasmodiidae|malaria fever|Fever, Remittent|Marsh Fever|Plasmodium Infections|Disease caused by Plasmodiidae|Malaria fever NOS|MALARIA|Malaria NOS|Remittent Fever | Malaria |
C0870868 | null | mediated response | mediated responses |
C0019113 | null | hemosiderin|Hemosiderins|Hemosiderin|haemosiderin|Haemosiderin|Hemosiderin (substance) | Hemosiderin |
C0023789 | A naturally occurring lipid pigment with histochemical characteristics similar to ceroid. It accumulates in various normal tissues and apparently increases in quantity with age. | lipofuscins|Lipofuscins|Lipofuscin|Senility pigment|lipofuscin | Lipofuscin |
C0206537 | A species of MORBILLIVIRUS causing distemper in seals. | Phocine distemper virus (organism)|Distemper Viruses, Phocine|Seal distemper virus|Phocid Distemper Viruses|phocine distemper virus PDV|Phocid Distemper Virus|Distemper Virus, Seal|Phocine morbillivirus|phocid distemper virus|Phocine Distemper Viruses|Distemper Viruses, Seal|phocid distemper virus PDV|phocine distemper virus|Distemper Viruses, Phocid|Phocine distemper virus|Phocine Distemper Virus|Distemper Virus, Phocid|Seal Distemper Viruses|Seal Distemper Virus | Distemper Virus, Phocine |
C0320994 | A species of MYXOSPOREA that causes whirling disease in salmonids. | Cerebrali, Myxobolus|Myxobolus cerebralis|Myxosoma cerebralis|Cerebralis, Myxobolus|Myxobolus Cerebrali|Myxosoma cerebralis (organism) | Myxobolus Cerebralis |
C0520797 | null | Twist disease|Whirling disease|Whirling disease (disorder) | Whirling disease |
C0030498 | Invertebrate organisms that live on or in another organism (the host), and benefit at the expense of the other. Traditionally excluded from definition of parasites are pathogenic BACTERIA; FUNGI; VIRUSES; and PLANTS; though they may live parasitically. | Parasite|parasite|Parasite (navigational concept)|parasitic|Parasites|Parasitic|Parasite, NOS|parasites|PARASITE | Parasites |
C0039593 | A procedure for critical evaluation; a means of determining the presence, quality, or truth of something. | testing|testing method|Test|Testing | Testing |
C0598782 | A natural prolongation or projection from a part of an organism either animal or plant; a part that is joined to something larger. | appendage|appendages | Appendage |
C1279062 | null | Entire cranium|Entire cranium (body structure) | Entire cranium |
C0030851 | The external reproductive organ of males. It is composed of a mass of erectile tissue enclosed in three cylindrical fibrous compartments. Two of the three compartments, the corpus cavernosa, are placed side-by-side along the upper part of the organ. The third compartment below, the corpus spongiosum, houses the urethra. | Penis|Penile structure|PENIS|Penis structure|Penile|Penile structure (body structure)|penis|penile|Penis, NOS|Genital System, Male, Penis|penis structure | penis |
C1155328 | Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a stimulus from a virus. [GOC:hb] | defence response to virus|defense response to viruses|defense response to virus|antiviral response|Anti-Viral Response|response to virus|response to viruses | Antiviral Response |
C0035028 | Activity which reduces the feelings of tension and the effects of STRESS, PHYSIOLOGICAL. | Relaxation|Relaxations|Relax|Relaxed|relaxation|relaxation (leisure) | Relaxation |
C0222660 | A type of osseous tissue which makes up the inner part of bone. It has a spongy, honeycomb-like structure with struts or trabecula and contains the BONE MARROW. It has higher rate of BONE REMODELING turnover than CORTICAL BONE. | Bone, Spongy|bone cancellous|Trabecular Bone|bone trabecular|cancellous bone|substantia spongiosa ossium|Trabecular bone|Trabecular substance of bone (body structure)|Trabecular substance of bone, NOS|Spongy Bone|Substantia trabecularis|Trabecular bone (tissue)|substantia trabecularis|Spongy bone|Trabecular substance of bone|Trabecular bone tissue|substantia spongiosa|Bones, Trabecular|bones trabecular|Trabecula|Bones, Cancellous|Bone, Cancellous|Cancellous bone|trabecula|Cancellous Bones|trabecular bone|spongy bone|Bones, Spongy|Substantia spongiosa|Trabecular Bones|Bone, Trabecular|cancellated bone|bone spongy|Spongy Bones|bones spongy | Cancellous Bone |
C0022122 | One of three bones that make up the coxal bone of the pelvic girdle. In tetrapods, it is the part of the pelvis that projects backward on the ventral side, and in primates, it bears the weight of the sitting animal. | ISCHIUM|Bone structure of ischium|Ischium, NOS|Hip|Ischium|Os ischii|ischium|Bone structure of ischium (body structure) | Bone structure of ischium |
C0222652 | null | cortex of bone|cortical bone|Cortex of bone|Cortex of bone (body structure)|Cortical bone | Cortex of bone |
Subsets and Splits
No saved queries yet
Save your SQL queries to embed, download, and access them later. Queries will appear here once saved.